Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group

被引：0
|
作者：
Schmiegel, W. H.
Reinacher-Schick, A.
Freier, W.
Dietrich, G.
Arnold, D.
Kanzler, S.
Geissler, M.
Graeven, U.
Hegewisch-Becker, S.
Schmoll, H.
机构：
[1] Ruhr Univ, Bochum, Germany
[2] Ctr Oncol, Hildesheim, Germany
[3] Bietigheim Hosp, Bietigheim, Germany
[4] Martin Luther Univ Halle Wittenberg, Halle, Germany
[5] Johannes Gutenberg Univ Mainz, Mainz, Germany
[6] Community Hosp, Esslingen, Germany
[7] Maria Hilf Hosp, Monchengladbach, Germany
[8] Ctr Oncol, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4034
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF IRINOTECAN, CAPECITABINE AND BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Garcia Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Giron, Carlos
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarnacion
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Oltra, Amparo
    Jose Gomez, Ma
    Manuel Campos, J.
    Aranda, Enrique
    ANNALS OF ONCOLOGY, 2012, 23 : 103 - 104
  • [22] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients
    Garcia Alfonso, Pilar
    Chaves-Conde, Manuel
    Munoz, Andres
    Salud, Antonia
    Garcia-Giron, Carlos
    Gravalos Castro, Cristina
    Massuti, Bartomeu
    Gonzalez Flores, Encarnacion
    Queralt, Bernardo
    Lopez Ladron, Amelia
    Losa, Ferran
    Oltra Ferrando, Amparo
    Gomez Reina, Maria Jose
    Garcia-Carbonero, Rocio
    Garcia-Escobar, Ignacio
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [23] RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer
    Wong, S. J.
    Winter, K.
    Meropol, N. J.
    Anne, R.
    Kachnic, L. A.
    Rashid, A.
    Watson, J. C.
    Mitchell, E. P.
    Pollock, J.
    Lee, R. J.
    Willett, C. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.
    Heinemann, V.
    Von Weikersthal, L. Fischer
    Moosmann, N.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [25] Phase II study of bevacizumab (BEV), weekly (wkly) intermittent capecitabine (Cap), and oxaliplatin (Ox) on an every-2-week schedule for patients (Pts) with untreated advanced colorectal cancer (CRC)
    Lembersky, B. C.
    Sehgal, R.
    Rajasenan, K. K.
    Crandall, T. L.
    Balaban, E. P.
    Pinkerton, R. A.
    Kane, P.
    Potter, D. M.
    Kinney, C.
    Ramanathan, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study
    Price, T. J.
    Townsend, A. R.
    Khattak, A.
    ANNALS OF ONCOLOGY, 2010, 21 (10) : 2121 - 2121
  • [27] Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater
    Overman, M. J.
    Varadhachary, G. R.
    Lin, E.
    Morris, J.
    Adinin, R.
    Abbruzzese, J. L.
    Wolff, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Phase II multicenter sequential study of oxaliplatin (O) and capecitabine (C) followed by irinotecan (I) and capecitabine (C) in first line advanced colorectal cancer (CRC).
    Cassinello, J
    Alvarez, JV
    García-López, MJ
    Pujol, E
    Colmenarejo, A
    de Segovia, F
    Marcos, F
    Filipovich, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 257S - 257S
  • [29] RADIATION THERAPY ONCOLOGY GROUP 0247: A RANDOMIZED PHASE II STUDY OF NEOADJUVANT CAPECITABINE AND IRINOTECAN OR CAPECITABINE AND OXALIPLATIN WITH CONCURRENT RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
    Wong, Stuart J.
    Winter, Kathryn
    Meropol, Neal J.
    Anne, Pramila Rani
    Kachnic, Lisa
    Rashid, Asif
    Watson, James C.
    Mitchell, Edith
    Pollock, Jondavid
    Lee, Robert Jeffrey
    Haddock, Michael
    Erickson, Beth A.
    Willett, Christopher G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04): : 1367 - 1375
  • [30] Sequential versus combination chemotherapy with capecitabine, irinotecan*, and oxaliplatin in advanced colorectal cancer: a Dutch Colorectal Cancer Group (DCCG) phase III study
    Koopman, M.
    Dourma, J.
    Wals, J.
    Honkoop, A. H.
    Erdkamp, F. L. G.
    de Jong, R. S.
    Rodenburg, C. J.
    Mol, L.
    Antonini, N. F.
    Punt, C. J. A.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (07) : A77 - A77
12345